Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $300000.0.

  • Myriad Genetics' Gains from Investment Securities fell 9000.0% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 4671.53%. This contributed to the annual value of $13.4 million for FY2024, which is 5227.27% up from last year.
  • Per Myriad Genetics' latest filing, its Gains from Investment Securities stood at $300000.0 for Q3 2025, which was down 9000.0% from $5.8 million recorded in Q1 2025.
  • In the past 5 years, Myriad Genetics' Gains from Investment Securities registered a high of $8.7 million during Q1 2024, and its lowest value of $200000.0 during Q2 2022.
  • For the 5-year period, Myriad Genetics' Gains from Investment Securities averaged around $2.8 million, with its median value being $1.8 million (2021).
  • In the last 5 years, Myriad Genetics' Gains from Investment Securities skyrocketed by 32500.0% in 2022 and then plummeted by 9000.0% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Gains from Investment Securities stood at $2.9 million in 2021, then tumbled by 48.28% to $1.5 million in 2022, then changed by 0.0% to $1.5 million in 2023, then dropped by 20.0% to $1.2 million in 2024, then crashed by 75.0% to $300000.0 in 2025.
  • Its Gains from Investment Securities was $300000.0 in Q3 2025, compared to $5.8 million in Q1 2025 and $1.2 million in Q4 2024.